Refractory gastro-oesophageal reflux disease: Diagnosis and management

Drugs

Volumn 69, Issue 14, 2009, Pages 1935-1944

  Liu, Julia J ^a   Saltzman, John R ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; ANTIINFECTIVE AGENT; AZATHIOPRINE; BACLOFEN; COLESTYRAMINE; CYCLOPHOSPHAMIDE; DAPSONE; DOMPERIDONE; DOXYCYCLINE; ERYTHROMYCIN; FLUTICASONE PROPIONATE; IRON SALT; METOCLOPRAMIDE; MONTELUKAST; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM CHLORIDE; PREDNISONE; PROTON PUMP INHIBITOR; QUINIDINE; TACROLIMUS; TETRACYCLINE; THEOPHYLLINE; TRIAMCINOLONE;

AMBULATORY MONITORING; ANATOMICAL VARIATION; CLINICAL EVALUATION; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DROWSINESS; DRUG DOSE REDUCTION; DRUG MEGADOSE; EOSINOPHILIC ESOPHAGITIS; ESOPHAGUS ACHALASIA; ESOPHAGUS MOTILITY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HEARTBURN; HUMAN; LIFESTYLE MODIFICATION; LOW FAT DIET; MANOMETRY; MULTI CHANNEL INTRALUMINAL IMPEDANCE TEST; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PH MEASUREMENT; POSTOPERATIVE COMPLICATION; REFLUX ESOPHAGITIS; REVIEW; SMOKING CESSATION; STOMACH EMPTYING; STOMACH FUNDOPLICATION; STOMACH PARESIS; WEIGHT REDUCTION;

CLINICAL PROTOCOLS; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC TECHNIQUES, DIGESTIVE SYSTEM; DRUG RESISTANCE; ENDOSCOPES, GASTROINTESTINAL; ESOPHAGEAL SPHINCTER, LOWER; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; HUMANS; PROTON PUMP INHIBITORS;

EID: 70349151364     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11318520-000000000-00000     Document Type: Review

References (51)

1. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002; 122 (5): 500-511
2. Dent J, El-Serag HB, Wallander MA, et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005 May; 54 (5): 710-717
3. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux is a strong risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-831
4. Shaheen NJ. Advances in Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology 2005 May; 128 (6): 1554-1566
5. Dent J, Dodds WJ, Friedman RH, et al. Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. J Clin Invest 1980 Feb; 65 (2): 256-267
6. Dodds WJ, Dent J, Hogan WJ, et al. Mechanisms of gastroesophageal reflux in patients with reflux esophagitis. N Engl J Med 1982 Dec 16; 307 (25): 1547-1552
7. Richter JE. How to manage refractory GERD. Nat Clin Pract Gastroenterol Hepatol 2007 Dec; 4 (12): 658-664
8. Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut 2009 Feb; 58 (2): 295-309
9. Bardhan KD. The role of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995; 9 Suppl. 1: 15-25
10. Martinez SD, Malagon IB, Garewal HS, et al. Non-erosive reflux disease (NERD): acid reflux and symptom patterns. Aliment Pharmacol Ther 2003 Feb 15; 17 (4): 537-545
11. Crawley JA, Schmitt CM. How satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs survey. J Clin Outcomes Manage 2000; 7 (11): 29-34
12. Kahrilas PJ, Shaheen NJ, Vaezi MF. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology 2008 Oct; 135 (4): 1392-1413, 413 e1-5
13. Vakil N, Moayyedi P, Fennerty MB, et al. Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. Gastroenterology 2006 Aug; 131 (2): 390-401; quiz 659-660
14. Barrison AF, Jarboe LA, Weinberg BM, et al. Patterns of proton pump inhibitor use in clinical practice. Am J Med 2001 Oct 15; 111 (6): 469-473
15. Gallup study of consumers' use of stomach relief products. Princeton (NJ): The Gallup Organization, 2000
16. Sgouros SN, Mantides A. Refractory heartburn to proton pump inhibitors: epidemiology, etiology and management. Digestion 2006; 73 (4): 218-227
17. Gupte AR, Draganov PV. Eosinophilic esophagitis. World J Gastroenterol 2009 Jan 7; 15 (1): 17-24
18. Abid S, Mumtaz K, Jafri W, et al. Pill-induced esophageal injury: endoscopic features and clinical outcomes. Endoscopy 2005 Aug; 37 (8): 740-744
19. Richter JE. The patient with refractory gastroesophageal reflux disease. Dis Esophagus 2006; 19 (6): 443-447
20. Keate RF, Williams JW, Connolly SM. Lichen planus esophagitis: report of three patients treated with oral tacrolimus or intraesophageal corticosteroid injections or both. Dis Esophagus 2003; 16 (1): 47-53
21. Hirschowitz BI, Simmons JL, Johnson LF, et al. Risk factors for esophagitis in extreme acid hypersecretors with and without Zollinger-Ellison syndrome. Clin Gastroenterol Hepatol 2004 Mar; 2 (3): 220-229
22. Furuta T, Shirai N, Sugimoto M, et al. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 2005 Jun; 20 (3): 153-167
23. Turner BG, Saltzman JR, Hua L, et al. Endoscopic pH monitoring for patients with suspected or refractory gastroesophageal reflux disease. Can J Gastroenterol 2007 Nov; 21 (11): 737-741
24. Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006 Oct; 55 (10): 1398-1402
25. Zerbib F, Roman S, Ropert A, et al. Esophageal pHimpedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 2006 Sep; 101 (9): 1956-1963
26. Fass R, Murthy U, Hayden CW, et al. Omeprazole 40mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastrooesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy: a prospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000 Dec; 14 (12): 1595-1603
27. Brillantino A, Monaco L, Schettino M, et al. Prevalence of pathological duodenogastric reflux and the relationship between duodenogastric and duodenogastrooesophageal reflux in chronic gastrooesophageal reflux disease. Eur J Gastroenterol Hepatol 2008 Dec; 20 (12): 1136-1143
28. Hoffman I, Tertychnyy A, Ectors N, et al. Duodenogastroesophageal reflux in children with refractory gastroesophageal reflux disease. J Pediatr 2007 Sep; 151 (3): 307-311
29. Burke CA, Achkar E, Falk GW. Effect of pneumatic dilation on gastroesophageal reflux in achalasia. Dig Dis Sci 1997 May; 42 (5): 998-1002
30. Jacobson BC, Somers SC, Fuchs CS, et al. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med 2006 Jun 1; 354 (22): 2340-2348
31. An evidence-based appraisal of reflux disease management: the Genval Workshop Report. Gut 1999; 44 Suppl. 2: S1-16
32. Fackler WK, Ours TM, Vaezi MF, et al. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002 Mar; 122 (3): 625-632
33. Katz PO, Anderson C, Khoury R, et al. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998 Dec; 12 (12): 1231-1234
34. Koek GH, Sifrim D, Lerut T, et al. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodenogastro- oesophageal reflux refractory to proton pump inhibitors. Gut 2003 Oct; 52 (10): 1397-1402
35. Connor F. Gastrointestinal complications of fundoplication. Curr Gastroenterol Rep 2005 Jun; 7 (3): 219-226
36. Peters JH,DeMeester TR, Crookes P, et al. The treatment of gastroesophageal reflux disease with laparoscopic Nissen fundoplication: prospective evaluation of 100 patients with "typical" symptoms. Ann Surg 1998; 228 (1): 40-50
37. DeMeester TR, Bonavina L, Albertucci M. Nissen fundoplication for gastroesophageal reflux disease: evaluation of primary repair in 100 consecutive patients. Ann Surg 1986; 204 (1): 9-20
38. Bittner HB, Meyers WC, Brazer SR, et al. Laparoscopic Nissen fundoplication: operative results and short-term follow-up. Am J Surg 1994 Jan; 167 (1): 193-8; discussion 9-200
39. Collard JM, de Gheldere CA, De Kock M, et al. Laparoscopic antireflux surgery: what is real progress? Ann Surg 1994 Aug; 220 (2): 146-154
40. Walker SJ, Baxter ST, Morris AI, et al. Review article: controversy in the therapy of gastro-oesophageal reflux disease. Long-termproton pump inhibition or laparoscopic anti-reflux surgery? Aliment Pharmacol Ther 1997 Apr; 11 (2): 249-260
41. Swoger J, Ponsky J, Hicks DM, et al. Surgical fundoplication in laryngopharyngeal reflux unresponsive to aggressive acid suppression: a controlled study. Clin Gastroenterol Hepatol 2006 Apr; 4 (4): 433-441
42. Mathew G, Watson DI, Myers JC, et al. Oesophageal motility before and after laparoscopic Nissen fundoplication. Br J Surg 1997 Oct; 84 (10): 1465-1469
43. Jamieson GG, Watson DI, Britten-Jones R, et al. Laparoscopic Nissen fundoplication. Ann Surg 1994 Aug; 220 (2): 137-145
44. Vakil N, Shaw M, Kirby R. Clinical effectiveness of laparoscopic fundoplication in a U.S. community [comment]. Am J Med 2003; 114 (1): 1-5
45. Watson DI, Jamieson GG, Baigrie RJ, et al. Laparoscopic surgery for gastro-oesophageal reflux: beyond the learning curve. Br J Surg 1996 Sep; 83 (9): 1284-1287
46. Triadafilopoulos G, Dibaise JK, Nostrant TT, et al. Radiofrequency energy delivery to the gastroesophageal junction for the treatment of GERD. Gastrointest Endosc 2001; 53 (4): 407-415
47. Filipi CJ, Lehman GA, Rothstein RI, et al. Transoral, flexible endoscopic suturing for treatment of GERD: a multicenter trial. Gastrointest Endosc 2001 Apr; 53 (4): 416-422
48. Deviere J, Costamagna G, Neuhaus H, et al. Nonresorbable copolymer implantation for gastroesophageal reflux disease: a randomized sham-controlled multicenter trial. Gastroenterology 2005 Mar; 128 (3): 532-540
49. Liu JJ, Carr-Locke DL, Lee LS, et al. Endoluminal gastroplication for treatment of patients with classic gastroesophageal reflux symptoms and borderline 24-h pH studies. Scand J Gastroenterol 2004 Jul; 39 (7): 615-620
50. Chen YK, Raijman I, Ben-Menachem T, et al. Longterm outcomes of endoluminal gastroplication: a U.S. multicenter trial. Gastrointest Endosc 2005 Jun; 61 (6): 659-667
51. Rothstein RI, Pohl H, Grove M, et al. Endoscopic gastric plication for the treatment ofGERD: two year follow-up results [abstract]. Am J Gastroenterol 2001; 96 (9 Suppl.): S35